» Articles » PMID: 18669498

Suicide Among Patients with Amyotrophic Lateral Sclerosis

Overview
Journal Brain
Specialty Neurology
Date 2008 Aug 2
PMID 18669498
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Studies on the suicide risk among patients with amyotrophic lateral sclerosis (ALS) in countries without legalized euthanasia or assisted suicide are important additions to data on the wish to die of these patients. We conducted a population-based cohort study in Sweden between 1965 and 2004, which comprised of 6,642 patients with incident ALS identified from the Swedish Inpatient Register. We calculated the standardized mortality ratios (SMRs) of suicide among the patients using the suicide rates of the general Swedish population as a reference. In total, 21 patients committed suicide during follow-up, compared to the predicted 3.6 suicides. Thus, we noted an almost 6-fold increased risk for suicide among ALS patients [SMR 5.8, 95% confidence interval (CI) 3.6-8.8]. Patients who committed suicide were, on average, around 7 years younger at the time of their first period of hospitalization than patients who did not commit suicide. The highest relative risk for suicide was observed within the first year after the patient's first period of hospitalization (SMR 11.2, 95% CI 5.8-19.6). After that, the relative risks decreased with time after hospitalization (P-value for trend = 0.006), but remained elevated 3 years later. The relative risks of suicide among ALS patients did not show a clear trend over time in contrast to the decreasing trend of relative risks for suicide among patients with cancer during the same period. Patients with ALS are at excess risk of suicide in Sweden and the relative risk is higher during the earlier stage of the disease.

Citing Articles

[End of life perspectives: a systematic survey of patients with amyotrophic lateral sclerosis].

Eickhoff C, Schone-Seifert B, Kettemann D, Bormann E, Grehl T, Boentert M Nervenarzt. 2024; 95(12):1131-1138.

PMID: 39545975 PMC: 11611964. DOI: 10.1007/s00115-024-01769-4.


Acceptance and Commitment Therapy for people living with motor neuron disease: an uncontrolled feasibility study.

Gould R, Rawlinson C, Thompson B, Weeks K, Gossage-Worrall R, Cantrill H Pilot Feasibility Stud. 2023; 9(1):116.

PMID: 37420261 PMC: 10327371. DOI: 10.1186/s40814-023-01354-7.


Causes of death among United States decedents with ALS: An eye toward delaying mortality.

Larson T, Goutman S, Davis B, Bove F, Thakur N, Mehta P Ann Clin Transl Neurol. 2023; 10(5):757-764.

PMID: 37000988 PMC: 10187717. DOI: 10.1002/acn3.51762.


Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study): A multicentre, open-label, dose-escalation phase 1 trial.

Imamura K, Izumi Y, Nagai M, Nishiyama K, Watanabe Y, Hanajima R EClinicalMedicine. 2022; 53:101707.

PMID: 36467452 PMC: 9716331. DOI: 10.1016/j.eclinm.2022.101707.


A randomised controlled trial of acceptance and commitment therapy plus usual care compared to usual care alone for improving psychological health in people with motor neuron disease (COMMEND): study protocol.

Gould R, Thompson B, Rawlinson C, Kumar P, White D, Serfaty M BMC Neurol. 2022; 22(1):431.

PMID: 36380299 PMC: 9664029. DOI: 10.1186/s12883-022-02950-5.